Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone for Opioid Withdrawal During Tapering
NCT03521960Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- May 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in opioid withdrawal syndrome (OWS) comparing Buspirone Arm with Placebo Arm (2 arms). Primary endpoints: Taper Completion at 28 days and Opioid Withdrawal Symptom Severity at 28 days. Started May 2018; status: completed.
02
Drugs
buspirone
03
Conditions
opioid withdrawal syndrome (OWS)
Beyond the preview
Go deeper on NCT03521960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03521960.